Clinical trial
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
NCT00334581 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00334581 |
|---|---|
| Title | Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria |
| Official title | A Study of Irbesartan 150mg Verses 300mg in Chinese Hypertensive Patients With Diabetes and Microalbuminuria |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Irbesartan |
| Enrollment | 192 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jun 8, 2006 |
| Last update posted | Sep 15, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: